Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
p38 MAP Kinase inhibitors as modulators of pro-inflammatory cytokine-expression for treatment of inflammation-related diseases like rheumatoid arthritis, inflammatory bowel disease, psoriasis, or acute coronary syndrome. More
BIS010 is a semi-synthetic plant origin polysaccharide demonstrating a potential modifying effect of the biologic activity of the joints. More
Anti-inflammatory drugs covalently linked to non-antibiotic macrolides. More
The University of Edinburgh has identified a hitherto unrecognised potential of IKr-specific Class III anti-arrhythmics for the treatment of inflammatory disorders in a number of disease states/models. More
The invention relates to the use of pro-inflammatory agents such as interleukin 8 (IL-8) in a treatment for Crohn's disease. More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us